Different Types of Regulation in Healthcare and Must Know to Build a Product

A digital health product can begin as a low-risk workflow tool and enter a heavily regulated category after one feature change. A medication reminder may function as a consumer wellness application. Add patient-specific dosing recommendations, and the product may require a new FDA assessment. A health application sold directly to consumers may operate outside HIPAA, but the same application could become subject to HIPAA when a hospital contracts with the developer to process protected health information.

The regulatory position can also change when the product adds:

• Clinical recommendations
• Artificial intelligence
• Electronic prescribing
• Claims or eligibility transactions
• Substance use disorder records
• EHR integrations
• Prior authorization
• Diagnostic testing
• Telehealth workflows
• Consumer tracking technologies

The right question is not simply, “Which healthcare regulations apply to software?”

Product teams must ask: Which regulations are activated by the product’s intended use, users, data, clinical influence, integrations, commercial model, and operating role?

This guide explains the principal healthcare product regulations that digital health startups, healthcare SaaS companies, health app developers, and enterprise innovation teams should evaluate before building or launching a product in the United States.

This guide provides a product-planning overview and does not replace legal, regulatory, clinical, or reimbursement advice for a specific product.

What Are Healthcare Product Regulations?

Healthcare product regulations are federal and state laws, agency rules, certification requirements, and program standards that govern how healthcare technology is developed, marketed, deployed, operated, and monitored.

They may determine:

• Which health information the product can collect
• How that information may be used or disclosed
• Whether software is considered a medical device
• How clinical recommendations must be validated
• How patients access electronic health information
• Which healthcare transactions and interoperability standards must be supported
• Who may provide care or prescribe medication
• How claims, referrals, and payments are handled
• Whether research or laboratory requirements apply
• How people with disabilities access digital services

A product may be subject to several regulatory systems simultaneously. 

A telehealth platform with clinical decision support, electronic prescribing, patient messaging, billing, and EHR connectivity has a much wider compliance surface than a standalone scheduling application.

Start With Product Classification, Not a HIPAA Checklist

Encryption, audit logging, and business associate agreements may be necessary, but they do not establish the product’s complete regulatory position.

Before design begins, document six factors.

1. Intended Use

Define what the product is intended to do, the problem it claims to solve, and the outcomes promoted through labeling, demonstrations, sales material, instructions, and customer agreements.

2. Intended Users

Identify whether the product is used by patients, caregivers, clinicians, payers, laboratories, researchers, pharmacists, administrators, or public health agencies.

3. Data Categories

Determine whether the product handles:

• Protected health information
• Consumer health data
• Substance use disorder records
• Children’s personal information
• Genetic or biometric information
• Clinical images
• Human specimens or laboratory results
• Claims and payment data

4. Clinical Influence

Establish whether the product merely displays information or whether it detects conditions, calculates risk, generates treatment recommendations, prioritizes patients, controls a device, or influences clinical decisions.

5. Commercial Model

Review who pays for the product and whether pricing, discounts, free services, commissions, referrals, prescriptions, claims, or federally reimbursed services are connected to the arrangement.

6. Operating Role

Determine whether the company functions as a software vendor, HIPAA business associate, healthcare provider, medical device manufacturer, certified health IT developer, laboratory, research sponsor, data processor, or another regulated actor.

These classifications should be reviewed whenever the product, customer, workflow, data source, AI model, or marketing claim changes.

7 Key Healthcare Product Regulations to Evaluate Before Development 

1. Healthcare Data Privacy and Security Regulations

HIPAA and HITECH

The HIPAA Privacy Rule applies to health plans, healthcare clearinghouses, and healthcare providers that conduct specified electronic healthcare transactions. Certain vendors also become business associates when they create, receive, maintain, or transmit PHI while performing services for a covered entity. Business associates are directly responsible for complying with specified HIPAA provisions.

A software company is therefore not automatically subject to HIPAA because its database contains health-related information.

A consumer medication tracker may operate outside HIPAA when individuals use it independently. The same platform could become a business associate when a provider contracts with the company to process PHI for care delivery or healthcare operations.

When HIPAA applies, the product and operating model should address:

• Permitted uses and disclosures
• Minimum-necessary access
• User authentication and authorization
• Audit controls
• Transmission and storage protection
• Risk analysis and risk management
• Incident response
• Backup and recovery
• Breach assessment and notification
• Business associate and subcontractor obligations

Following a breach of unsecured PHI, covered entities may have to notify affected individuals, HHS, and, in some circumstances, the media. Business associates must notify the relevant covered entity when a breach occurs at the business associate.

The proposed HIPAA Security Rule modernization should not be described as current law. HHS has proposed more prescriptive requirements concerning asset inventories, risk analysis, encryption, multifactor authentication, network segmentation, contingency planning, testing, and documentation. 

Until a final rule takes effect, teams must distinguish existing requirements from future-facing design preparation.

HIPAA Administrative Simplification

HIPAA is not limited to privacy and security.

Administrative Simplification establishes national standards for electronic healthcare transactions, code sets, unique identifiers, and operating rules. These standards are relevant to products supporting claims, eligibility, claim status, payment and remittance, enrollment, referral authorization, and pharmacy transactions.

A healthcare billing or payer product should determine:

• Whether it creates or transmits a covered transaction
• Which ASC X12 or NCPDP standard applies
• Which code sets and identifiers are required
• Whether applicable operating rules are supported
• How acknowledgements, rejections, corrections, and reconciliation are managed

FHIR support does not replace adopted HIPAA transaction standards where those standards remain legally required.

FTC Health Breach Notification Rule

Applications outside HIPAA do not operate in a regulatory vacuum.

The FTC Health Breach Notification Rule applies to certain vendors of personal health records and related entities that are not covered by HIPAA. 

The 2024 amendments clarified the rule’s application to health apps, connected devices, and similar products. Covered organizations may have to notify consumers, the FTC, and, in some cases, the media after a breach of unsecured, individually identifiable health information.

A breach can involve an unauthorized disclosure by the business itself, not only an external cyberattack. Product teams must therefore examine analytics tools, advertising pixels, SDKs, AI subprocessors, crash-reporting services, and cloud integrations against actual privacy representations and user permissions.

State Consumer Health Privacy Laws

State laws can protect health information that is not PHI under HIPAA.

Washington’s My Health My Data Act includes requirements concerning consumer health data privacy notices, collection and sharing, consumer rights, processors, data security, authorization for sale, and certain geofencing practices.

California’s CCPA provides rights to know, delete, correct, and opt out of certain sales or sharing of personal information. It also allows consumers to limit specified uses and disclosures of sensitive personal information.

A national consumer health product may need jurisdiction-aware controls for:

• Notice and consent
• Access and deletion requests
• Correction
• Sale or sharing opt-outs
• Retention
• Processor agreements
• Sensitive-data limitations
• Tracking technologies

A single generic privacy toggle is unlikely to support every applicable state requirement.

42 CFR Part 2

Products handling records from federally assisted substance use disorder programs may also be subject to 42 CFR Part 2.

The 2024 Part 2 Final Rule became effective in April 2024, and compliance was required by February 2026. The rule permits, subject to its conditions, a single consent for future treatment, payment, and healthcare operations uses and disclosures.

Product teams should preserve the source, consent status, and legal handling requirements of Part 2 records. They should implement the access, disclosure, consent, or segmentation controls needed to prevent unauthorized use.

Segmentation is an engineering approach, not a universally prescribed technical architecture. The legal requirement is to ensure that the resulting uses and disclosures comply with Part 2.

COPPA

COPPA applies to online services directed to children under 13 and to other operators with actual knowledge that they collect personal information online from a child under 13.

The FTC amended the COPPA Rule in 2025, including new restrictions involving children’s data use and third-party advertising. Pediatric product teams should assess parental notice, verifiable parental consent, data minimization, retention, security, disclosures, and age-assurance processes.

2. FDA Regulations for Digital Health Products

Not every healthcare application is a medical device.

FDA analysis begins with the software function’s intended use and whether it meets the statutory definition of a device. FDA applies a risk-based approach to device software functions, and some software functions are outside the device definition or are subject to enforcement-discretion policies.

Low-risk products intended to maintain or encourage a general state of health may fit FDA’s General Wellness policy. FDA issued an updated final General Wellness guidance in January 2026.

FDA also issued updated final Clinical Decision Support Software guidance in January 2026. Certain HCP-facing CDS functions can be excluded from the definition of a device when they satisfy all applicable statutory criteria, including enabling the healthcare professional to independently review the basis for the recommendation.

If software is a medical device, the manufacturer must determine:

• Device classification
• Applicable general and special controls
• Whether premarket submission is required
• Whether the path is 510(k), De Novo, PMA, or another route
• Software and cybersecurity documentation
• Analytical and clinical validation
• Labeling and intended-use controls
• Registration and listing obligations
• Complaint and adverse-event processes
• Postmarket monitoring
• Change-control requirements

FDA classifies devices as Class I, II, or III. 

The applicable premarket pathway and controls depend on classification, risk, predicate availability, and the specific device type—not merely the presence of software or AI.

QMSR and Product Development

The FDA Quality Management System Regulation became effective on February 2026. The revised 21 CFR Part 820 incorporates ISO 13485:2016 by reference and applies to finished device manufacturers intending to commercially distribute medical devices.

A regulated medical device product should not attempt to reconstruct compliance evidence just before submission.

Quality processes should cover:

• Design and development planning
• Risk management
• Requirements and traceability
• Verification and validation
• Supplier controls
• Change control
• Complaint handling
• Corrective and preventive action
• Record control
• Postmarket feedback

AI-Enabled Device Changes

FDA’s final guidance on predetermined change control plans explains how a manufacturer may describe planned modifications to an AI-enabled device, the methodology for developing and validating those modifications, and the assessment of their impact.

A PCCP does not authorize unlimited retraining. Changes must remain within the reviewed plan and continue to provide reasonable assurance of safety and effectiveness.

3. Interoperability and Certified Health IT Regulations

Information Blocking

The information blocking regulations apply to defined actors, including healthcare providers, health information networks or exchanges, and developers of certified health IT.

Product features, fees, contracts, API restrictions, export limitations, or access delays can create information-blocking risk when the organization is a regulated actor, the practice interferes with access, exchange, or use of electronic health information, and no applicable exception is satisfied.

Not every software vendor is automatically an information-blocking actor. The organization’s role and certified product activities must be evaluated.

HTI-1, USCDI, and Predictive Algorithms

HTI-1 established transparency requirements for predictive algorithms included in certified health IT through the Decision Support Interventions certification criterion. Developers must support specified source attributes and risk-management information for applicable evidence-based and predictive interventions.

HTI-1 also adopted USCDI Version 3 as the baseline within the ONC Health IT Certification Program from January 2026.

Certified product roadmaps must account for:

• Required data classes and elements
• Terminology standards
• C-CDA and FHIR implementation requirements
• API certification criteria
• Testing tools
• Maintenance-of-certification obligations
• Customer upgrade plans

HTI-4

HTI-4 added or updated certification criteria for electronic prescribing, real-time prescription benefit information, and electronic prior authorization. It also includes related API functionality and standards supporting clinical and administrative exchange with payers.

Applicability and implementation dates vary by criterion. Product teams should map each certification requirement to their actual module and release roadmap rather than assuming every HTI-4 provision became mandatory at once.

CMS-0057-F

CMS-0057-F affects specified Medicare Advantage organizations, Medicaid and CHIP programs and plans, and qualified health plan issuers on federally facilitated exchanges.

Several operational requirements began January 2026. These include specified prior-authorization decision timeframes and reporting obligations. Impacted payers, excluding QHP issuers on the FFEs for the decision-timeframe requirement, generally must send decisions within 72 hours for expedited requests and seven calendar days for standard requests.

The principal API requirements apply beginning primarily on January 2027, and cover:

• Patient Access API enhancements
• Provider Access API
• Payer-to-Payer API
• Prior Authorization API

Compliance requires more than exposing a FHIR endpoint. Products must address authorization, patient attribution, implementation-guide conformance, terminology, consent, provenance, status management, denials, error handling, monitoring, and reconciliation with payer and provider source systems.

4. Telehealth, Licensure, and Electronic Prescribing

Healthcare professional licensure is primarily state-based.

A telehealth encounter generally occurs in the state where the patient is located. Providers must be licensed or otherwise legally permitted to practice in that jurisdiction. Available pathways may include a full license, temporary practice authority, reciprocity, a compact, or telehealth registration.

A telehealth product should support:

• Patient-location verification
• Provider license status
• Scope-of-practice restrictions
• Telehealth consent
• State-specific documentation
• Prescribing eligibility
• Emergency escalation
• Professional-liability considerations

Electronic prescribing of controlled substances adds federal requirements. 

Only applications meeting DEA requirements under 21 CFR Part 1311 may be used to electronically create, sign, transmit, receive, archive, or dispense controlled-substance prescriptions.

EPCS products require appropriate identity proofing, access controls, authentication, signing, audit, and recordkeeping capabilities.

5. Accessibility and Nondiscrimination Requirements

Accessibility should be treated as a product requirement, not a final design review.

HHS Section 504 regulations require covered recipients of HHS federal financial assistance to make applicable web content and mobile applications conform to WCAG 2.1 Level AA, subject to defined exceptions and limitations. In May 2026, HHS extended the compliance dates to:

• May 2027, for recipients with 15 or more employees
• May 2028, for recipients with fewer than 15 employees

Relevant product controls include keyboard navigation, screen-reader semantics, captions, text alternatives, accessible forms, focus management, contrast, scalable text, and accessible authentication.

Products may also require review under the Americans with Disabilities Act, Section 1557, and state nondiscrimination laws. 

HHS announced in June 2026 that a federal court had vacated specific gender-identity provisions of the 2024 Section 1557 rule, while other protections remain in effect. Product teams should obtain current legal review before relying on a simplified summary of Section 1557 obligations.

6. Fraud, Abuse, Billing, and Reimbursement Rules

Healthcare product compliance also depends on how the software influences referrals, claims, prescriptions, and payment. The Federal Anti-Kickback Statute prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce or reward referrals or business involving items or services payable by federal healthcare programs. 

Remuneration may include cash, free services, discounts, technology, or other value.

Safe harbors protect specified arrangements that satisfy all applicable conditions. They are not automatic approvals for every technology arrangement.

The False Claims Act creates liability for knowingly submitting or causing false claims to be submitted to the federal government. “Knowingly” can include actual knowledge, deliberate ignorance, or reckless disregard.

Products should be reviewed carefully when they:

• Recommend billable services
• Generate diagnosis or procedure codes
• Automate clinical documentation
• Submit claims
• Route referrals
• Calculate patient responsibility
• Provide free technology to referral sources
• Receive compensation based on referrals or claims

Automation should preserve the relationship between the service performed, documentation, code selected, claim submitted, corrections made, and approving user.

7. Research and Laboratory Regulations

Digital health companies may use patient information to train models, validate algorithms, conduct clinical studies, or measure outcomes.

The Common Rule establishes basic requirements involving institutional review boards, informed consent, and assurances for covered human-subject research.

Research may involve human subjects when an investigator obtains, uses, studies, analyzes, or generates identifiable private information or identifiable biospecimens about a living individual.

FDA human-subject protection requirements, HIPAA research provisions, state law, and contractual obligations may also apply depending on the study.

CLIA

CLIA generally applies to a facility that performs even one applicable test on material derived from the human body to provide information for diagnosis, prevention, treatment, or health assessment.

A software vendor that only transports, stores, or displays laboratory results is not automatically a CLIA laboratory.

If the company operates a facility performing patient-specific testing or assumes responsibility for those testing activities, it should determine the required CLIA certificate, test-complexity category, personnel standards, quality controls, validation requirements, and applicable state laboratory laws.

AI Is a Cross-Regulatory Function

There is no single federal healthcare AI compliance certificate. An AI feature may be affected by:

• FDA medical device requirements
• HIPAA
• FTC privacy and consumer-protection rules
• State privacy laws
• ONC certification requirements
• Civil rights and nondiscrimination laws
• Professional-practice rules
• Research regulations
• Fraud and abuse requirements
• Customer governance and contractual controls

The AI product record should document:

• Intended and excluded uses
• Training and validation data rights
• Model inputs and outputs
• Validation populations
• Performance limitations
• Human review
• Bias and subgroup testing
• Version history
• Drift monitoring
• Override behavior
• Incident response
• Rollback controls

How to Build Regulatory Readiness Into Product Engineering

Step 1: Define and Control Intended Use

Create one approved intended-use statement that product, engineering, clinical, regulatory, marketing, and sales teams use consistently.

Step 2: Map Actors and Data Flows

Document every user, customer, system, dataset, API, model, processor, purpose, destination, and jurisdiction.

Step 3: Build an Applicability Matrix

For every potentially applicable rule, identify:

• Why it applies
• The regulated actor
• The affected product function
• The legal or regulatory requirement
• The chosen engineering control
• Required evidence
• The accountable owner
• The release gate

Step 4: Separate Obligations From Implementations

Regulations typically define required outcomes. Architecture determines how the product achieves and proves those outcomes.

Regulatory outcome	Possible product implementation
Prevent unauthorized disclosure	Consent-aware authorization or data segmentation
Protect electronic PHI	Encryption, MFA, monitoring, and tested recovery
Support patient access	Standards-based export and API workflows
Validate device performance	Requirements traceability and verification evidence
Prevent unsupported claims	Evidence linkage and human approval controls
Provide accessible digital services	Accessible design system and manual testing

Step 5: Generate Evidence During Development

Maintain architecture decisions, risk assessments, traceability, validation results, accessibility reports, supplier reviews, security tests, model documentation, change approvals, and incident exercises as the product is developed.

Step 6: Establish Regulatory Release Gates

Before release, confirm that:

• Intended use has not materially changed
• Product classification remains valid
• Required assessments are complete
• Verification and validation have passed
• Customer-facing claims match available evidence
• Contracts and subprocessors are current
• Monitoring, incident response, and rollback are operational
• Required regulatory or certification submissions are complete

Common Healthcare Product Compliance Mistakes

The most damaging failures often begin before coding:

• Assuming every health app is covered by HIPAA
• Treating HIPAA as the only privacy requirement
• Calling a diagnostic feature “wellness” without assessing its function and claims
• Adding AI without reassessing intended use
• Treating a business associate agreement as a security program
• Sending health-related data to advertising or analytics platforms without proper review
• Building one national telehealth workflow without state-specific logic
• Treating FHIR connectivity as complete interoperability
• Generating claims or codes without evidence traceability
• Adding accessibility after development
• Using patient data for model training without confirming authority
• Launching without complaint, incident, monitoring, and change-control processes

Build the Regulatory Path Before Building the Product

Healthcare product compliance should not be handled as a legal checklist added shortly before launch.

Regulations shape the product itself.

They determine which information can be collected, who may access it, which recommendations may be produced, how algorithms can change, how information must be exchanged, what evidence must be retained, and when a release requires additional review.

The strongest product teams classify the product early, convert approved regulatory requirements into engineering controls, produce evidence continuously, and reassess applicability whenever the product’s function, customer, data, clinical influence, integration, or commercial model changes.

Build Regulatory-Ready Healthcare Products With CapMinds

CapMinds helps digital health startups, healthcare SaaS companies, and enterprise innovation teams translate approved legal, regulatory, security, and interoperability requirements into product architecture, engineering controls, testing, traceability, and release evidence.

Our healthcare product engineering capabilities include:

• Regulatory-readiness architecture assessments
• HIPAA-aligned healthcare application engineering
• FDA-aware medical device software development
• AI governance and human-review workflows
• FHIR, HL7, EHR, and payer API integration
• Identity, consent, audit, and data-governance controls
• Telehealth and electronic prescribing workflows
• Accessibility engineering and testing
• Healthcare cybersecurity and cloud security
• Validation, traceability, release governance, and post-launch monitoring

Plan Your Healthcare Product Compliance Architecture With CapMinds

Schedule a Free Strategy Call